Press releasePRNewswire
PTC Therapeutics
PTCT · NASDAQ
$62.92+$1.39 (+2.26%)TodayMarket closed ·
Prev close $61.53
Latest news
- Press releasePRNewswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Press releasePRNewswire
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
- Press releasePRNewswire
PTC Therapeutics to Participate in Upcoming Investor Conferences
- Press releasePRNewswire
PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile
- NewsVandana Singh
PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity'
- News
PTC Therapeutics To Acquire BLA-Stage ST-920 Fabry Disease Program; Terms Include $111M Upfront And Up To $100M In Contingent Milestone Payments Based On Certain Regulatory Approvals
- Press releasePRNewswire
PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program
- Press releasePRNewswire
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
- Press releasePRNewswire
Hamilton Lane Board Elects Michael Schmertzler as New Independent Director
- Press releasePRNewswire
PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026
- Press releasePRNewswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Press releasePRNewswire
PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes
- Press releasePRNewswire
PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- News
PTC Therapeutics Q1 EPS $(0.03) Beats $(0.48) Estimate, Sales $272.551M Beat $218.805M Estimate
- Press releasePRNewswire
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
- Press releasePRNewswire
PTC Therapeutics to Participate in Upcoming Investor Conferences
- NewsVandana Singh
PTC Therapeutics Stock Sinks As Pivotal Data Fails To Calm Sellers
- Press releasePRNewswire
PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam
- Press releasePRNewswire
PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study
- Press releasePRNewswire
PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026
- Press releasePRNewswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Press releasePRNewswire
PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors
- Press releasePRNewswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Press releasePRNewswire
PTC Therapeutics to Participate at Upcoming Investor Conferences
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- Press releasePRNewswire
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
- News
Earnings Scheduled For February 19, 2026
- Press releasePRNewswire
Phenylketonuria Market to Reach New Heights by 2034, Driven by Innovative Therapies and Rising Diagnosis Rates | DelveInsight
- News
Earnings Outlook For PTC Therapeutics
- NewsVandana Singh
PTC Therapeutics Pulls Translarna Bid After FDA Flags Weak Proof
- Press releasePRNewswire
PTC Therapeutics Provides Regulatory Update on Translarna™
- Press releasePRNewswire
PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026
- NewsVandana Singh
What's Going On With Royalty Pharma Stock Wednesday?
- NewsAvi Kapoor
Amazon To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.